Kura Oncology (KURA) Current Leases (2019 - 2026)

Kura Oncology (KURA) has 8 years of Current Leases data on file, last reported at $1.3 million in Q1 2026.

• Quarterly Current Leases fell 32.65% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 32.65% YoY) and the FY2025 annual result came in at $1.3 million, down 32.11% from the prior year.
• Current Leases steadied at $1.3 million in Q1 2026 per KURA's latest filing, from $1.3 million in the prior quarter.
• Across five years, Current Leases topped out at $2.3 million in Q2 2023 and bottomed at $1.3 million in Q4 2025.
• The 5-year median for Current Leases is $1.7 million (2025), against an average of $1.8 million.
• The widest annual swing landed in 2024, when Current Leases tumbled 41.55%; it then surged 39.77% in 2025.
• Tracing KURA's Current Leases over 5 years: stood at $2.3 million in 2022, then sank by 35.03% to $1.5 million in 2023, then gained by 24.9% to $1.9 million in 2024, then tumbled by 32.11% to $1.3 million in 2025, then gained by 0.47% to $1.3 million in 2026.
• Per Business Quant, the three latest KURA Current Leases figures stand at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q3 2025).

Peer Comparison